American Journal of Clinical Dermatology

, Volume 6, Issue 3, pp 175–184 | Cite as

Non-Acne Dermatologic Indications for Systemic Isotretinoin

Review Article


Systemic isotretinoin has been used to treat severe acne vulgaris for 20 years. However, isotretinoin also represents a potentially useful choice of drugs in many dermatologic diseases other than acne vulgaris. Diseases such as psoriasis, pityriasis rubra pilaris, condylomata accuminata, skin cancers, rosacea, hidradenitis suppurativa, granuloma annulare, lupus erythematosus and lichen planus have been shown to respond to the immunomodulatory, anti-inflammatory and antitumor activities of the drug. Isotretinoin also helps prevent skin cancers such as basal cell carcinoma or squamous cell carcinoma. A combination of systemic isotretinoin and interferon-α-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment of skin cancers.

Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities. However, randomized clinical trials aimed at determining the role of systemic isotretinoin therapy in dermatologic diseases other than acne vulgaris are required.


Retinoid Isotretinoin Rosacea Hidradenitis Suppurativa Cutaneous Lupus Erythematosus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.


  1. 1.
    Orfanos CE, Zouboulis CC, Almond-Roesler B, et al. Current use and future potential role of retinoids in dermatology. Drugs. 1997; 53: 358–88PubMedCrossRefGoogle Scholar
  2. 2.
    Jones H, Blanc D, Cunliffe WJ. 13-cis retinoic acid and acne. Lancet. 1980 Nov 15; 2: 1048–9PubMedCrossRefGoogle Scholar
  3. 3.
    Zoubolis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology. 2003; 206: 37–53CrossRefGoogle Scholar
  4. 4.
    Coble BI, Dahlgren C, Molin L, et al. Neutrophil function in psoriasis: effects of retinoids. Acta Derm Venereol. 1987; 67: 481–90PubMedGoogle Scholar
  5. 5.
    Lehman PA, Henderson WR. Retinoid-induced inhibition of eosinophil LTC4 production. Prostaglandins. 1990; 39: 569–77PubMedGoogle Scholar
  6. 6.
    Gollnick HPM, Dümmler U. Retinoids. Clin Dermatol. 1997; 15: 799–810PubMedCrossRefGoogle Scholar
  7. 7.
    Zoubolis CC. Retinoids: which dermatologic indications will benefit in the near future?. Skin Pharmacol Appl Skin Physiol. 2001; 14: 303–15Google Scholar
  8. 8.
    Lefebvre P. Molecular basis for designing selective modulators of retinoic acid receptors transcriptional activities. Curr Drug Targets Immune Endocr Metabol Disord. 2001; 1: 153–64PubMedCrossRefGoogle Scholar
  9. 9.
    Arechalde A, Samat J-H. Management of psoriasis: the position of retinoid drugs. BioDrugs. 2000; 13: 327–33PubMedCrossRefGoogle Scholar
  10. 10.
    Recchia F, De Flippis S, Rossetti M, et al. Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase two study. Int J Oncol. 2002; 20: 1275–82PubMedGoogle Scholar
  11. 11.
    Somos S, Farkas B. Immunomodulatory treatment of with low dose interferon and oral retinoic acid in lymphangioma like Kaposi sarcoma. Anticancer Res. 2000; 20: 541–5PubMedGoogle Scholar
  12. 12.
    Holland DB, Gowland G, Cunliffe WJ. Inflammatory responses in acne patients treated with 13-cis-retinoic acid (isotretinoin). Br J Dermatol. 1984; 110: 343–5PubMedCrossRefGoogle Scholar
  13. 13.
    Watson RR, Jackson JC, Alberts DS, et al. Cellular immune functions of adults treated with a daily, long term, low dose of 13-cis retinoic acid. J Leukoc Biol. 1986; 39: 567–77PubMedGoogle Scholar
  14. 14.
    Dillehay DL, Jiang XL, Lamon EW. Differential effects of retinoids on pokeweed mitogen induced-B cell proliferation vs immunoglobulin synthesis. Int J Immunopharmacol. 1991; 13: 1043–8PubMedCrossRefGoogle Scholar
  15. 15.
    Fahlman C, Jacobsen SE, Smeland EB, et al. All-trans and 9-cis retinoic acid inhibit growth of normal human and munine B cell precursors. J Immunol. 1995; 155: 58–65PubMedGoogle Scholar
  16. 16.
    Adelman DC, Yen TY, Cumberland BG, et al. 13-cis retinoic acid enhances in vivo B lymphocyte differentiation in patients with common variable immunodeficiency. J Allergy Clin Immunol. 1991; 88: 705–12PubMedCrossRefGoogle Scholar
  17. 17.
    Saxon A, Keld B, Braun J, et al. Long-term administration of 13-cis retinoic acid in common variable immunodeficiency: circulating IL-6 levels, B-cell surface molecule display, and in vitro and in vivo B-cell antibody production. Immunology. 1993; 80: 477–87PubMedGoogle Scholar
  18. 18.
    Worm M, Krah JM, Manz RA, et al. Retinoic acid inhibits CD 40 + interleukin-4-mediated IgE production in vitro. Blood. 1998; 92: 1713–20PubMedGoogle Scholar
  19. 19.
    Worm M, Herz U, Krah JM, et al. Effects of retinoids on in vitro and in vivo IgE production. Int Arch Allergy Immunol. 2001; 124: 233–6PubMedCrossRefGoogle Scholar
  20. 20.
    Wozel G, Chang A, Zultak M, et al. The effects of topical retinoids on the leukotriene-B4-induced migration of polymorphonuclear leukocytes into human skin. Arch Dermatol Res. 1991; 283: 158–61PubMedCrossRefGoogle Scholar
  21. 21.
    Piattelli A, Fioroni M, Santinelli A, et al. Bel-2 expression and apoptotic bodies in 13-cis retinoic acid (isotretinoin) topically treated oral leukoplakia: a pilot study. Oral Oncol. 1999; 35: 314–20PubMedCrossRefGoogle Scholar
  22. 22.
    Moon TE, Levine N, Cartmel B, et al. Retinoids in prevention of skin cancer. Cancer Lett. 1997; 114: 203–5PubMedCrossRefGoogle Scholar
  23. 23.
    DiGiovanna JJ. Posttransplantation skin cancer: scope of the problem, management, and role for systemic retinoid chemoprevention. Transplant Proc. 1998; 30: 2771–5PubMedCrossRefGoogle Scholar
  24. 24.
    Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition. 2000; 16: 1084–90PubMedCrossRefGoogle Scholar
  25. 25.
    Lingen MW, Polverini PJ, Bouck NP. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest. 1996; 74: 476–83PubMedGoogle Scholar
  26. 26.
    Karukonda SRK, Flynn TC, Bob EE, et al. The effects of drug on wound healing. Part II. Specific classes of drugs and their effect on healing wounds. Int J Dermatol. 2000; 39: 321–33PubMedCrossRefGoogle Scholar
  27. 27.
    Weninger W, Rendl M, Mildner M, et al. Retinoids downregulate vascular endothelial growth factor/vascular permeability factor production by normal human keratinocytes. J Invest Dermatol. 1998; 111: 907–11PubMedCrossRefGoogle Scholar
  28. 28.
    Pili R, Kruszewski MP, Hager BW, et al. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 2001; 61: 1477–85PubMedGoogle Scholar
  29. 29.
    Majewski S, Szmurlo A, Marczak M, et al. Synergistic effects of retinoids and interferon alpha on tumor-induced angiogenesis: antiangiogenic effect on HPV-harboring tumor-cell lines. Int J Cancer. 1994; 57: 81–5PubMedCrossRefGoogle Scholar
  30. 30.
    Shklar G, Schwartz J. Tumor necrosis factor in experimental cancer regression with alphatocopherol, beta-carotene, canthaxantine and algae extract. Fur J Cancer Clin Oncol. 1988; 24: 839–50CrossRefGoogle Scholar
  31. 31.
    Schwartz JL, Shklar G. Retinoid and carotenoid angiogenesis: a possible explanation for enhanced oral carcinogenesis [abstract]. Nutr Cancer. 1997; 28: 218CrossRefGoogle Scholar
  32. 32.
    Vahlquist A, Rollman O. Clinical pharmacology of three generations of retinoids. Dermatologica. 1987; 1: 20–7CrossRefGoogle Scholar
  33. 33.
    Colburn WA, Gibson DM, Wiens RE, et al. Food increases the bioavailability of isotretinoin. J Clin Pharmacol. 1983; 23: 534–9PubMedGoogle Scholar
  34. 34.
    Avis I, Mathias A, Unsworth EJ, et al. Analysis of small cell lung cancer growth inhibition by 13-cis-retinoic acid: importance of bioavailability. Cell Growth Differ. 1995; 6: 485–92PubMedGoogle Scholar
  35. 35.
    Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhoea and acne. Dermatology. 1998; 196 (1): 140–7PubMedCrossRefGoogle Scholar
  36. 36.
    Kerr IG, Lippman ME, Jenkins J, et al. Pharmacology of 13-cis-retinoic acid in humans. Cancer Res. 1982; 42: 2069–73PubMedGoogle Scholar
  37. 37.
    Larsen FG, Nielsen-Kudsk F, Jakobsen P, et al. Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases. Clin Pharmacokinet. 1992; 23: 42–61PubMedCrossRefGoogle Scholar
  38. 38.
    Vane FM, Bugge CJ, Rodriguez LC, et al. Human biliary metabolites of isotretinoin: identification, quantification, synthesis, and biological activity. Xenobiotica. 1990; 20: 193–207PubMedCrossRefGoogle Scholar
  39. 39.
    Nulman I, Berkovitch M, Klein J, et al. Steady-state pharmacokinetics of isotretinoin and its 4-oxometabolite: implication for fetal safety. J Clin Pharmacol. 1998; 38: 926–30PubMedGoogle Scholar
  40. 40.
    Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 1982; 6: 710–5PubMedCrossRefGoogle Scholar
  41. 41.
    Cardamakis E, Kotoulas LG, Relakis K, et al. Comparative study of systemic interferon alfa-2A plus isotretinoin versus isotretinoin in the treatment of recurrent condyloma acuminatum in men. Urology. 1995; 45: 857–60PubMedCrossRefGoogle Scholar
  42. 42.
    Tsambaos D, Georgiou S, Monastirli A, et al. Treatment of condylomata acuminata with oral isotretinoin. J Urol. 1997; 158: 1810–2PubMedCrossRefGoogle Scholar
  43. 43.
    Peck GL, DiGiovanni JJ, Sarnoff DS, et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol. 1988; 19: 176–85PubMedCrossRefGoogle Scholar
  44. 44.
    Tangrea JA, Adrianza E, Helsel WE, The Isotretinoin Basal Cell Carcinomas Study Group, et al. Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: incidence and risk factors. Cancer Epidemiol Biomarkers Prev. 1993; 2 (4): 375–80PubMedGoogle Scholar
  45. 45.
    Skeet RT, Huang J, Manola J, et al. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893). Cancer Invest. 2003; 21: 41–6CrossRefGoogle Scholar
  46. 46.
    Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002; 20: 364–70PubMedCrossRefGoogle Scholar
  47. 47.
    Triozzi PL, Walker MJ, Pellegrini AE, et al. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest. 1996; 14: 293–8PubMedCrossRefGoogle Scholar
  48. 48.
    Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981; 47 (1): 207–14PubMedCrossRefGoogle Scholar
  49. 49.
    Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996; 34: 1022–9PubMedCrossRefGoogle Scholar
  50. 50.
    Erdogan FG, Yurtsever P, Aksoy D, et al. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998; 134: 884–5PubMedCrossRefGoogle Scholar
  51. 51.
    Nikolowski J, Plewig G. Oral treatment of rosacea with 13-cis retinoic acid. Hautarzt. 1981; 32: 575–84PubMedGoogle Scholar
  52. 52.
    Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa [abstract]. J Am Acad Dermatol. 1999; 41: 658Google Scholar
  53. 53.
    Honigsmann H, Wolff K. Isotretinoin-PUVA for psoriasis [letter]. Lancet. 1983; I: 236CrossRefGoogle Scholar
  54. 54.
    Sofen EL, Moy RL, Lowe NJ. Treatment of generalised pustular psoriasis with isotretinoin [letter]. Lancet. 1984; 7: 40CrossRefGoogle Scholar
  55. 55.
    Moy RL, Kingston TP, Lowe NJ. Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol. 1985; 121: 1297–301PubMedCrossRefGoogle Scholar
  56. 56.
    Ansley A, Hawk JLM. Isotretinoin-PUVA in women with psoriasis. Br J Dermatol. 1997; 136: 798–9CrossRefGoogle Scholar
  57. 57.
    Clayton BD, Jorizzo JL, Hitchcock MK, et al. Adult pityriasis rubra pilaris: a 10-year case series. J Am Acad Dermatol. 1997; 36: 959–64PubMedCrossRefGoogle Scholar
  58. 58.
    Peck GL, Yoder FW, Olsen TG, et al. Treatment of Darier’s disease, lamellar ichthyosis, pityriasis rubra pilaris, cystic acne, and basal cell carcinoma with oral 13-cis retinoic acid (isotretinoin). Dermatologica. 1978; 157 Suppl. 1: 11–2PubMedCrossRefGoogle Scholar
  59. 59.
    Gilgor RS, Chiaramonti A, Goldsmith LA, et al. Evaluation of 13-cis-retinoic acid in lamellar ichthyosis, pityriasis rubra pilaris and Darier’s disease. Cutis. 1980; 25: 380–5PubMedGoogle Scholar
  60. 60.
    Risch J, Ashton RE, Lowe N. 13-cis-retinoic acid for dyskeratinizing diseases: clinicopathologic responses. Clin Exp Dermatol. 1984; 9: 472–83PubMedCrossRefGoogle Scholar
  61. 61.
    Dicken CH. Isotretinoin treatment of pityriasis rubra pilaris. J Am Acad Dermatol. 1987; 16: 297–301PubMedCrossRefGoogle Scholar
  62. 62.
    Olsen EA, Kelly FF, Vollmer RT, et al. Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata. J Am Acad Dermatol. 1989; 20: 1023–30PubMedCrossRefGoogle Scholar
  63. 63.
    Lambrinos P, Cardamakis E, Michopoulos J, et al. Comparative study of systemic interferon alfa-2a plus isotretinoin vs isotretinoin in the treatment of recurrent condylomata acuminata [abstract]. Gynecol Endocrinol. 1993; 17 Suppl. 1: 109Google Scholar
  64. 64.
    Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with oral isotretinoin. N Engl J Med. 1988; 318: 1633–7PubMedCrossRefGoogle Scholar
  65. 65.
    Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized double-blind controlled trial. Cancer Epidemiol Biomarkers Prev. 1997; 6: 949–56PubMedGoogle Scholar
  66. 66.
    Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of beta-carotene to prevent basal cell and squamous cell carcinoma of the skin. N Engl J Med. 1990; 323: 789–95PubMedCrossRefGoogle Scholar
  67. 67.
    Ellis CN, Kracht KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001; 45: S150–7PubMedCrossRefGoogle Scholar
  68. 68.
    Sander CA, Pfeifer C, Kligman AM, et al. Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol. 1997; 36: 236–8PubMedCrossRefGoogle Scholar
  69. 69.
    Majewski S, Skopinska M, Bollag W, et al. Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions [letter]. Lancet. 1994; 344: 1510–1PubMedCrossRefGoogle Scholar
  70. 70.
    Skopinska M, Majewski S, Bolleg W, et al. Calcitriol and isotretinoin combined therapy for precancerous and cancerous skin lesions. J Dermatol Treat. 1997; 8: 5–10CrossRefGoogle Scholar
  71. 71.
    Dragnev KH, Rigas JR, Dimitrovsky E. The retinoids and cancer prevention mechanisms. Oncologist. 2000; 5: 361–8PubMedCrossRefGoogle Scholar
  72. 72.
    Tangrea JA, Edwards BK, Taylor PR, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinic trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Nall Cancer Inst. 1992; 84: 328–32CrossRefGoogle Scholar
  73. 73.
    Goldberg L, Hsu S, Alcalay J. Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J Am Acad Dermatol. 1989; 21: 144–5PubMedCrossRefGoogle Scholar
  74. 74.
    Rudkin GH, Carlsen BT, Chung CY, et al. Retinoids inhibit squamous cell carcinoma growth and intercellular communication. J Surg Res. 2002; 103: 183–9PubMedCrossRefGoogle Scholar
  75. 75.
    Lippman SM, Parkinson DR, Itri LM, et al. 13-cis retinoic acid and interferon alpha-2a: effect of combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst. 1992; 84: 241–5PubMedCrossRefGoogle Scholar
  76. 76.
    Eisenhauer EA, Lippman SM, Kavanagh JJ, et al. Combination 13-cis retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia. 1994; 8: 1622–5PubMedGoogle Scholar
  77. 77.
    Toma S, Palumbo R, Vincenti M, et al. Efficiency of recombinant alpha-interferon 2a and 13-cis retinoic acid in the treatment of squamous cell carcinoma. Ann Oncol. 1994; 5: 463–5PubMedGoogle Scholar
  78. 78.
    Nijsten TEC, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol. 2003; 49: 644–50PubMedCrossRefGoogle Scholar
  79. 79.
    Schaber B, Mayer P, Schreiner T, et al. Anti-proliferative activity of natural interferon-alpha, isotretinoin and their combination varies in different human melanoma cell lines. Melanoma Res. 1994; 4: 319–26PubMedCrossRefGoogle Scholar
  80. 80.
    Edwards L, Meyskens F, Levine N. Effect of oral isotretinoin on dysplastic nevi. J Am Acad Dermatol. 1989; 20: 257–60PubMedCrossRefGoogle Scholar
  81. 81.
    Bearzatto A, Orlandi L, Silvestrini R, et al. Combined effects of interferon-alpha2a and 13-cis-retinoic acid on human melanoma cell growth and STAT protein expression. Melanoma Res. 1998; 8: 31–8PubMedCrossRefGoogle Scholar
  82. 82.
    Rosenthal MA, Oratz R. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma. Am J Clin Oncol. 1998; 212: 352–4CrossRefGoogle Scholar
  83. 83.
    Bunn PA, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med. 1994; 121: 592–602PubMedGoogle Scholar
  84. 84.
    Kessler JF, Meyskens FL, Levine N, et al. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet. 1983; I (8338): 1345–7CrossRefGoogle Scholar
  85. 85.
    Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate: a study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1987; 67: 232–6PubMedGoogle Scholar
  86. 86.
    Neely SM, Mehlmauer M, Feinstein DI. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch Intern Med. 1987; 147: 529–31PubMedCrossRefGoogle Scholar
  87. 87.
    Burg G, Dummer R. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL). Clin Lymphoma. 2000; 1 Suppl. 1: S41–4PubMedGoogle Scholar
  88. 88.
    Gupta AK, Chaudry MM. Critical review of the manner in which the efficacy of therapies for rosacea are evaluated. Int J Dermatol. 2003; 42: 909–16PubMedCrossRefGoogle Scholar
  89. 89.
    Rebora A. The management of rosacea. Am J Clin Dermatol. 2002; 3: 489–96PubMedCrossRefGoogle Scholar
  90. 90.
    Firooz A, Firoozabadi MR, Doelati Y. Rosacea fulminans (pyoderma faciale): successful treatment of a 3-year old girl with oral isotretinoin. Int J Dermatol. 2001; 40 (3): 203–5PubMedCrossRefGoogle Scholar
  91. 91.
    Jansen T, Romiti R, Kreuter A, et al. Rosacea fulminans triggered by high-dose vitamins B6 and B12. J Fur Acad Dermatol Venereol. 2001; 15: 484–5CrossRefGoogle Scholar
  92. 92.
    Slade DEM, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg. 2003; 56: 451–61PubMedCrossRefGoogle Scholar
  93. 93.
    Jansen T, Altmeyer P, Piewig G. Acne inversa (alias hidradenitis suppurativa). J Fur Acad Dermatol Venereol. 2001; 15: 532–40CrossRefGoogle Scholar
  94. 94.
    Brown CF, Gallup DG, Brown VM. Hidradenitis suppurativa of the anogenital region: response to isotretinoin. Am J Obstet Gynecol. 1988; 158: 12–5PubMedGoogle Scholar
  95. 95.
    Schleicher SM, Milstein HJ. Resolution of disseminated granuloma annulare following isotretinoin therapy. Cutis. 1985; 36: 147–8PubMedGoogle Scholar
  96. 96.
    Ratnavel RC, Norris PG. Perforating granuloma annulare: response to treatment with isotretinoin. J Am Acad Dermatol. 1995; 32: 126–7PubMedCrossRefGoogle Scholar
  97. 97.
    Adams DC, Hogan DJ. Improvement of chronic generalized granuloma annulare with isotretinoin. Arch Dermatol. 2002; 138: 1518–9PubMedCrossRefGoogle Scholar
  98. 98.
    Tang WYM, Chung LY, Lo K. Resolution of generalized granuloma annulare with isotretinoin therapy. Int J Dermatol. 1996; 35: 455–6PubMedCrossRefGoogle Scholar
  99. 99.
    Erkek E, Karaduman A, Bdkülmez N, et al. An usual form of generalized granuloma annulare in a patient with insulin-dependent diabetes mellitus. Acta Derm Venerol. 2001; 81: 48–50PubMedCrossRefGoogle Scholar
  100. 100.
    Green SG, Piette WW. Successful treatment of hypertrophic lupus erythematosus with isotretinoin. J Am Acad Dermatol. 1987; 17: 364–8PubMedCrossRefGoogle Scholar
  101. 101.
    Furner BB. Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol. 1990; 29: 587–90PubMedCrossRefGoogle Scholar
  102. 102.
    Shormick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol. 1991; 24: 49–52CrossRefGoogle Scholar
  103. 103.
    Richardson TT, Cohen PR. Subacute cutaneous lupus erythematosus: report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin. Cutis. 2000; 66: 183–8PubMedGoogle Scholar
  104. 104.
    Handler HL. Isotretinoin for oral lichen planus [letter]. J Am Acad Dermatol. 1984; 10: 674PubMedCrossRefGoogle Scholar
  105. 105.
    Woo TY. Systemic isotretinoin treatment of oral and cutaneous lichen planus. Cutis. 1985; 35: 385–6PubMedGoogle Scholar
  106. 106.
    Camisa C, Allen CM. Treatment of oral erosive lichen planus with systemic isotretinoin. Oral Surg Oral Med Oral Pathol. 1986; 62: 393–6PubMedCrossRefGoogle Scholar
  107. 107.
    Carlin CS, Florell SR, Krueger GG. Induction of dramatic hyperpigmentation in a patient with generalized lichen planus treated with re-PUVA. J Cutan Med Surg. 2002; 6: 125–7PubMedCrossRefGoogle Scholar
  108. 108.
    Statham BN, Cunliffe WJ. The treatment of steatocystoma multiplex suppurativum with isotretinoin [letter]. Br J Dermatol. 1984; 111: 246PubMedCrossRefGoogle Scholar
  109. 109.
    Schwartz JL, Goldsmith LA. Steatocystoma multiplex suppurativum: treatment with isotretinoin. Cutis. 1984; 34: 149–50PubMedGoogle Scholar
  110. 110.
    Friedman SJ. Treatment of steatocystoma multiplex and pseudofolliculitis barbae with isotretinoin. Cutis. 1987; 39: 506–7PubMedGoogle Scholar
  111. 111.
    Apaydin R, Bilen N, Bayramgurler D, et al. Steatocystoma multiplex suppurativum: oral isotretinoin treatment combined with cryotherapy. Australas J Dermatol. 2000; 41: 98–100PubMedCrossRefGoogle Scholar
  112. 112.
    Hodge JA, Ray MC. Confluent and reticulated papillomatosis: response to isotretinoin [letter]. J Am Acad Dermatol. 1991; 24: 654PubMedCrossRefGoogle Scholar
  113. 113.
    Lee MP, Stiller MJ, McClain SA, et al. Confluent and reticulated papillomatosis: response to high-dose oral isotretinoin therapy and reassessment of epidemiologic data. J Am Acad Dermatol. 1994; 31: 327–31PubMedCrossRefGoogle Scholar
  114. 114.
    Solomon BA, Laude TA. Two patients with confluent and reticulated papillomatosis: response to oral isotretinoin and 10% lactic acid lotion. J Am Acad Dermatol. 1996; 35: 645–6PubMedCrossRefGoogle Scholar
  115. 115.
    Spielvogel RL, DeVillez RL, Roberts LC. Oral isotretinoin therapy for familial Muir-Torre syndrome. J Am Acad Dermatol. 1985; 12: 475–80PubMedCrossRefGoogle Scholar
  116. 116.
    Marcusson JA, Bjarnason B, Ros AM. Isotretinoin for sebaceous skin lesions in Muir-Torre syndrome: a case report. Acta Derm Venereol. 1998; 78: 479–80PubMedCrossRefGoogle Scholar
  117. 117.
    Graefe T, Wollina U, Schulz H, et al. Muir-Torre syndrome: treatment with isotretinoin and interferon alpha-2a can prevent tumour development. Dermatology. 2000; 200: 331–3PubMedCrossRefGoogle Scholar
  118. 118.
    Rubeiz N, Kibbi A-G. Management of ichthyosis in infants and children. Clin Dermatol. 2003; 21: 325–8PubMedCrossRefGoogle Scholar
  119. 119.
    Baden HP, Buxman MM, Weinstein GD, et al. Treatment of ichthyosis with isotretinoin. J Am Acad Dermatol. 1982; 6 (4 Pt 2 Suppl.): 716–20PubMedCrossRefGoogle Scholar
  120. 120.
    Venkataram M. Epidermolytic hyperkeratosis: failure of retinoid therapy. Retinoids. 2002; 18: 71–2Google Scholar
  121. 121.
    Milam CP, Cohen LE, Fenske NA, et al. Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol. 1988; 19: 469–77PubMedCrossRefGoogle Scholar
  122. 122.
    Hisler BM, Savoy LB, Hashimoto K. Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol. 1991; 24: 854–7PubMedCrossRefGoogle Scholar
  123. 123.
    Berbis P, Privat Y. Lupus miliaris disseminatus faciei: efficacy of isotretinoin. J Am Acad Dermatol. 1987; 16: 1271–2PubMedCrossRefGoogle Scholar
  124. 124.
    Bahadir S, Apaydin R, Cimsit G, et al. Oral isotretinoin in two patients with lupus miliaris disseminatus faciei. J Dermatol Treat. 1999; 10: 205–8CrossRefGoogle Scholar
  125. 125.
    Omulecki A, Dabkowski J, Zak-Prelich M, et al. Perifolliculitis capitis abscedens et suffodiens — a case report. Med Sci Monit. 2000; 6: 602–4PubMedGoogle Scholar
  126. 126.
    Scavo S, Dnazuso GL, La Rocca R, et al. Isotretinoin in perifollicultis capitis absceden et suffodiens: a case report and review of the literature. Clin Drug Invest. 2002; 22: 791–4CrossRefGoogle Scholar
  127. 127.
    Atom K, Aivaliotis M, Davaris P. Disseminated and recurrent infundibular folliculitis (D.R.I.F.): report of a case successfully treated with isotretinoin. J Dermalot. 1998; 25: 51–3Google Scholar
  128. 128.
    Çalka Ö, Metin A, Özen S. A case of disseminated and recurrent infundibulofol-liculitis responsive to treatment with systemic isotretinoin. J Dermatol. 2002; 29: 431–4PubMedGoogle Scholar
  129. 129.
    Layton AM, Cunliffe WJ. A case of ulerythema ophryogenes responding to isotretinoin. Br J Dermatol. 1993; 129: 645–6PubMedCrossRefGoogle Scholar
  130. 130.
    Gruss C, Zillikens D, Hashimoto T, et al. Rapid response of IgA pemphigus of subcomeal pustular dermatosis type to treatment with isotretinoin. J Am Acad Dermatol. 2000; 43: 923–6PubMedCrossRefGoogle Scholar
  131. 131.
    Akyol M, Dogan S, Kaptanoglu E, et al. Systemic isotretinoin in the treatment of a Behcet’s patient with arthritic symptoms and acne lesions [letter]. Clin Exp Rheumatol. 2002; 20 (4 Suppl. 26): S–55PubMedGoogle Scholar
  132. 132.
    Bachynsky T, Antonyshyn OM, Ross JB. Dissecting folliculitis of the scalp: a case report of combined treatment using tissue expansion, radical excision, and isotretinoin. J Dermatol Surg Oncol. 1992; 18: 877–80PubMedGoogle Scholar
  133. 133.
    Weisshaar E, Schramm M, Gollnick H. Familial nevoid sebaceous gland hyperplasia affecting three generations of a family. Fur J Dermatol. 1999; 9: 621–3Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Dermatology DepartmentSchool of Medicine of Cumhuriyet UniversitySivasTurkey

Personalised recommendations